Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The document serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific insider transaction and does not contain consolidated financial statements.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a specific share transaction by Ms. C. Thomas:
- Option Exercise: On November 9, 2011, Ms. Thomas exercised options over 45,000 Ordinary shares granted on December 3, 2002, at a price of £11.79 per share.
- Share Sale: On November 9, 2011, 42,028 Ordinary shares were sold at a price of £13.77 per share.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory notification of a director's share transaction.
Investor Verification Points
- Verify the total number of shares held by Ms. C. Thomas following the exercise and sale.
- Confirm the timing of the transaction notification to the company (November 10, 2011).
- Review the original grant date (December 3, 2002) and exercise price (£11.79) to assess the economic benefit realized.